Mary Motyl

Merck & Co., Inc., Rahway, NJ, USA (United States)

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia”.

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Journal of Antimicrobial Chemotherapy(2021)10.1093/jac/dkab494

N/A

0DataRank · unranked

22 citations

Jean‐François Timsit, Marin H. Kollef, Richard G. Wunderink, Nobuaki Shime, Martin Nováček +12 more